Optimizerx Corp SEC Filings

OptimizeRx Corp (OPRX) insider transaction on 10/03/2025: Chief Executive Officer Stephen L. Silvestro had 6,649 restricted stock units vest and convert one-for-one into common stock, increasing his beneficial holdings to 190,536 shares. To satisfy tax withholding obligations, 1,620 shares were withheld and treated as a disposition at a price of $18.75, leaving 188,916 shares beneficially owned. The filing notes the RSUs vest in three equal annual installments beginning 10/03/2023. The reported transactions were certified on 10/07/2025.

OptimizeRx Corp director and Chief Finance & Strategy Officer Edward Stelmakh reported transactions on 10/03/2025 showing the vesting and conversion of 16,623 restricted stock units into common shares. After the transactions, he beneficially owned 127,387 shares. The filing shows 4,406 shares were withheld to satisfy tax-withholding obligations, treated as a disposition at $18.75 per share for a net increase of 16,623 shares from the RSU vesting. The RSUs vest in three equal annual installments beginning on 10/03/2023.

OptimizeRx Corp (OPRX) reporting person Doug Besch had 3,325 restricted stock units vest on 10/03/2025, which converted one‑for‑one into 3,325 shares of common stock at a zero exercise price. Following the vesting, the reporting person beneficially owned 70,555 shares. The issuer withheld 983 shares to satisfy tax withholding obligations at a price of $18.75, treated as a disposition for Section 16 purposes, leaving 69,572 shares shown as directly owned after that disposition. The RSUs vest in three equal annual installments beginning 10/03/2023. The filing was signed by power of attorney on 10/07/2025.

OptimizeRx Corp (OPRX) reported that Andrew J. D'Silva, the company's Chief Business Officer and a director, received equity awards on 08/21/2025. He was granted 10,417 restricted stock units (RSUs) that represent a contingent right to receive common stock and 23,437 stock options with an exercise price of $16.14. After these grants, Mr. D'Silva beneficially owns 47,514 shares23,437 option-related shares exercisable into common stock.

The RSUs and the stock option award both vest in three equal annual installments beginning on 08/21/2026, the first anniversary of the grant, with the option expiring on 08/21/2030. The filing is a Form 4 reporting the grant; it includes a customary remark clarifying that the filing is not an admission of beneficial ownership for Section 16 purposes.

OptimizeRx Corp (OPRX) officer Andrew J. D'Silva reported beneficial ownership of 37,097 shares of common stock, including 24,890 shares represented by unvested restricted stock units (RSUs). The filing lists five stock option grants covering 78,626 underlying shares with exercise prices of $7.20, $67.31, $15.04, $12.73, and $4.95 and exercisable on dates through 10/01/2029. Several RSU and option tranches vest between 10/01/2025 and 12/19/2026.

OptimizeRx director Patrick D. Spangler reported selling 11,120 shares of OptimizeRx Corp (OPRX) on 08/28/2025 at a weighted average price of $17.49 per share, with individual sale prices ranging from $17.47 to $18.43. After the reported disposition the filing shows the reporting person beneficially owned 44,215 shares, held directly. The Form 4 indicates the sale was executed in multiple transactions and the filer offers to provide detailed per-price allocation on request. The statement is limited to this single non-derivative sale and includes a standard reservation that the filer does not concede beneficial ownership for all purposes.

OptimizeRx Corporation (OPRX) notice reports a proposed sale under Rule 144 of 11,120 shares of common stock, with an aggregate market value of $198,000. The filing identifies the broker as Merrill, 80 South 8th Street, Minneapolis, MN, and lists the approximate date of sale as 08/28/2025 on Nasdaq. The shares were acquired through a series of restricted stock awards from OptimizeRx between March 31, 2019 and March 31, 2020, with vesting/payment dates shown in 2019–2020. The filer states there were no securities sold in the past three months and certifies no undisclosed material adverse information is known.

OptimizeRx Corp (OPRX) reporting person Stephen L. Silvestro, identified as Chief Executive Officer and Director, reported acquisitions on 08/21/2025. He was granted 15,625 restricted stock units (RSUs) that carry a contingent right to receive common shares and will vest in three equal annual installments beginning August 21, 2026. He also received a stock option for 35,156 shares with an exercise price of $16.14; the option vests in three equal annual installments beginning August 21, 2026 and is exercisable from August 21, 2026 through August 21, 2030. Following these reported transactions, the filing shows 183,887 shares of common stock and 35,156 derivative securities beneficially owned. The Form 4 was signed by power of attorney on August 25, 2025.

OptimizeRx officer Marion K. Odence-Ford was granted 15,625 restricted stock units and a stock option for 35,156 shares on 08/21/2025. The RSUs vest in three equal annual installments beginning 08/21/2026. The option has an exercise price of $16.14, vests in three equal annual installments beginning 08/21/2026, is exercisable 08/21/2026 and expires 08/21/2030. Following the awards, Odence-Ford beneficially owns 85,901 shares of common stock and holds options/rights covering 35,156 additional shares.